Keytruda (pembrolizumab)

pCPA File Number: 21649
Negotiation Status:
Under consideration for negotiation
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Merck Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable